论文部分内容阅读
目的:探讨保妇康栓联合派特灵治疗宫颈高危型人乳头瘤病毒(HR-HPV)感染的临床效果。方法:将90例宫颈HR-HPV阳性患者随机分为观察组(n=45)与对照组(n=45)进行治疗。观察组采用保妇康栓和派特灵联合用药;对照组只用保妇康栓,15天为一个疗程,共2个疗程。观察治疗后HPV转阴情况。结果:观察组转阴39例,转阴率86.7%;对照组转阴21例,转阴率46.7%。观察组优于对照组,转阴率高于对照组(P<0.05)。结论:保妇康栓与派特联合用药能有效治疗宫颈高危型人乳头瘤病毒感染。
Objective: To investigate the clinical effect of Baofukang Suppository combined with Pei-ling in the treatment of cervical high-risk human papillomavirus (HR-HPV) infection. Methods: 90 cases of cervical HR-HPV positive patients were randomly divided into observation group (n = 45) and control group (n = 45) for treatment. The observation group was used Baofukang suppository and Patrician combination; the control group only Baofukang suppository, 15 days for a course of treatment, a total of 2 courses. Observe HPV negative after treatment. Results: In the observation group, there were 39 cases of negative conversion and the negative conversion rate was 86.7%. In the control group, 21 cases were negative conversion and the negative conversion rate was 46.7%. The observation group was better than the control group, the negative conversion rate was higher than that of the control group (P <0.05). Conclusion: Baofukang Suppository combined with Pat can effectively treat cervical high risk human papillomavirus infection.